Vertex Ventures HC
San Francisco, California, United StatesFounded 2014
Vertex Ventures HC (VVHC) is a women-led global healthcare venture capital firm backed by Vertex Holdings, investing in life sciences and medical technology companies from early-stage through commercialization. Its portfolio spans biopharmaceuticals, medical devices, diagnostics, and digital health.
68% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $83.2M (across 24 rounds with reported amounts).
Portfolio
17
Fund Size
$200M
Top Stage
Series A
Last 12 Mo
0
Team
CB
Christine Brennan
Managing Director
LH
Lori Hu
Managing Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
25 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| SSpyGlass Pharma, Inc | Series D | — | Jun 2025 |
 Spyglass | Series D | $75M | Jun 2025 |
 Indapta Therapeutics | Unknown | $22.5M | Dec 2024 |
 TORL Biotherapeutics | Series B | $158M | Apr 2024 |
| Indapta Therapeutics | Unknown | $22.5M | Jan 2024 |
| Spyglass | Series C | $90M | Jul 2023 |
 SonoThera | Series A | $60.8M | Jan 2022 |
| Indapta Therapeutics | Series A | $60M | Jan 2022 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
 Sonoma Biotherapeutics | Series B | $265M | Aug 2021 |
 Neuspera Medical | Series C | $65M | Jul 2021 |
 Palleon Pharmaceuticals | Series B | $100M | Sep 2020 |
| Palleon Pharmaceuticals | Series B | $100M | Jan 2020 |
 Epirium Bio | Series A | $85M | Dec 2019 |
 Epirium Bio | Series A | $85M | Jan 2019 |
| Epirium Bio | Series A | $85M | Jan 2019 |
 Bicycle Therapeutics | Seed | $27.9M | Jan 2018 |
| Palleon Pharmaceuticals | Unknown | $47.6M | Oct 2017 |
| Bicycle Therapeutics | Series B | $40M | Jan 2017 |
| SonoThera | Series B | $125M | — |
 Matchpoint Therapeutics | Series A | $70M | — |
| EEyebiotech Limited | Series A | $65M | — |
| OObsidian Therapeutics, Inc. | Series A | $160.5M | — |
 Moximed | Growth | $40M | — |
 Elevation Oncology | Series A | $32.5M | — |
Top Co-Investors
RA Capital Management9 shared
Cormorant Asset Management7 shared
Samsara BioCapital6 shared
ARCH Venture Partners6 shared
Deep Track Capital5 shared
Alexandria Venture Investments5 shared
SR One5 shared
Bristol Myers Squibb4 shared
Atlas Venture4 shared
Surveyor Capital4 shared
Takeda Ventures, Inc.4 shared
New Enterprise Associates4 shared
Perceptive Advisors3 shared
GV3 shared
Leaps by Bayer3 shared
AbbVie3 shared
Pfizer Ventures3 shared
Longitude Capital3 shared
Adams Street Partners3 shared
Bluebird Ventures3 shared
Last updated: 7 October 2026